Charles River Labs
1Q Revenues: $299.4 million (+3%)
1Q Earnings: $32.4 million (+26%)
Comments: RMS segment sales were $185.6 million in the quarter, up 2%, with growth in the Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $113.8 million, up 5% driven by continued demand from mid-tier biotechnology clients.
Please visit our sister sites:
